Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains how the implementation of the Oncology Care Model (OCM) allowed practices to better integrate palliative care.
Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, explains how the implementation of the Oncology Care Model (OCM) allowed practices to better integrate palliative care.
Transcript
How has the implementation of the OCM allowed practices to better integrate palliative care, and what impact does that have?
The practice transformation plan, which is really the heart of the Oncology Care Model, requires that we provide a patient a 13-point institute of medicine care plan, and one of those is either survivorship care planning for patients whose trajectory is survivorship and end of life, and part of that is really when the patient actually understands that the cancer has progressed and then the conversation starts. RCCA’s approach to this is it doesn’t matter, as long as you have spoken to the patient about cancer therapy. It may not be the metastatic type.
But I think in any chronic disease, not just cancer, we should really have a conversation with the patient about advanced care planning. Who is their healthcare proxy? Because that is pretty much a non-threatening or not very uncomfortable to talk about. In my family, we have already spoken about that. So, the conversation is a little bit lighter rather than a patient who is already in palliative care or you’re going to tell the patient we’re going to start you on palliative care and they don’t even have a healthcare proxy. It’s a big challenge.
OCM has really paved the way. We use it as the standard of care for cancer because it requires that. In the OCM model, it is very difficult to succeed if you don’t have end of life, palliative care that includes palliative care and hospice and actually bereavement as part of its services. We have to really think about the patient’s outcomes, which include financial outcomes for the patients, as well as the total patient experience. It has to be part of that. If you start asking about their healthcare proxy, when the time comes, you just move along the conversation and say, “Ok, Suzy is you’re proxy, now we’re going to think about your cancer has progressed, what is next?” So, then if the patient is in pain, we’re going to talk about palliation, so you really are informing the caregivers of the patient what could be next. So, it’s not going to be such an uncomfortable conversation anymore.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Expanding Access to NSCLC Innovations: Challenges and Opportunities
October 18th 2024The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
Read More
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More